CervoMed Inc. Files 8-K

TL;DR

CervoMed filed an 8-K, likely containing important updates.

AI Summary

CervoMed Inc. filed an 8-K on July 23, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or details about the nature of the disclosure.

Why It Matters

This 8-K filing indicates that CervoMed Inc. has made a regulatory disclosure and submitted financial statements and exhibits to the SEC.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for disclosure and exhibits, with no immediate indication of significant negative events.

Key Players & Entities

• CervoMed Inc. (company) — Registrant
• 0001053691 (company) — Central Index Key
• 20 Park Plaza, Suite 424 Boston, Massachusetts 02116 (company) — Principal Executive Office Address

FAQ

Key Financial Figures

• $0.001 — on which registered Common Stock , $0.001 par value CRVO NASDAQ Capital Market

Filing Documents

• crvo20240722_8k.htm (8-K) — 32KB
• 0001437749-24-023240.txt ( ) — 161KB
• crvo-20240723.xsd (EX-101.SCH) — 3KB
• crvo-20240723_def.xml (EX-101.DEF) — 11KB
• crvo-20240723_lab.xml (EX-101.LAB) — 15KB
• crvo-20240723_pre.xml (EX-101.PRE) — 11KB
• crvo20240722_8k_htm.xml (XML) — 3KB

01

Item 7.01 Regulation FD Disclosure Virtual Key Opinion Leader Event As previously announced, on July 23, 2024, CervoMed Inc. (the "Company," "we," or "us") will host a virtual key opinion leader event related to neflamapimod for the treatment of patients with dementia with Lewy bodies. Certain information concerning the business, clinical studies, development plans, financial position and related matters to be presented during the event has been made available on our website, www.cervomed.com, under the heading, "Investors – Events and Presentations." Representatives of the Company may also use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with other conferences, meetings, and presentations to investors, analysts and others. The information contained in the presentation is summary information that is intended to be considered in the context of the Company's filings with the Securities and Exchange Commission ("SEC") and other public announcements that we may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure. The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K. The information in this Item 7.01 (including any information incorporated herein by reference) is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: July 23, 2024 CervoMed Inc. By: /s/ William Elder Name: William Elder Title: Chief Financial Officer & General Counsel 3

View Full Filing

View this 8-K filing on SEC EDGAR